# FDA 483 - Sajjad A. Sabir, M.D. - May 23, 2024

Source: https://www.keypedia.com/records/483/sajjad-a-sabir-md/5c29708d-e060-4b5b-a0f6-b062edeb99c2

> FDA 483 for Sajjad A. Sabir, M.D. on May 23, 2024. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Sajjad A. Sabir, M.D.
- Inspection Date: 2024-05-23
- Product Type: drugs
- Office Name: New Jersey District Office
- Summary: An FDA inspection of Sajjad A. Sabir, M.D., a clinical investigator in Camden, NJ, revealed significant deficiencies in record-keeping and adherence to investigational plans. Observations included documenting study visits for deceased subjects and failing to properly report adverse events and conduct follow-up visits according to protocol. These issues indicate serious concerns regarding data integrity and patient safety in clinical trials.

## Related Officers

- [investigator](https://www.keypedia.com/people/tyanna-n-hadley/8fdebfd7-d6f3-44ab-9dcb-864ab6d55d53)

Company: https://www.keypedia.com/companies/sajjad-a-sabir-md/0c550ab5-820b-40d3-a623-b650903e1705

Office: https://www.keypedia.com/offices/new-jersey-district-office/6ff5e2e9-5cff-44c7-af24-5a55329a8248